Download - Treating your Skin cancer - pt -update
ANDREW STYPEREK MD
Treating your Skin cancer
TAMARAC
7301 N University Drive, Suite 102
Tamarac, FL 33321
Phone: 954-726-2000
Quick Facts
#1 cancer in America, ~ 2M cases annuallyNo precursor lesionAggressive and Non-aggressive subtypesLocal destructive growthMetastasis: < 1/1000
Quick Facts
#2 cancer, ~ 1M cases annuallyPrecursor lesions for most types of SCC
Lifetime risk of SCC if have pre-cancers: 6-10%Aggressive and Non-aggressive subtypesLocal destructive growth which may track
along nervesMetastasis: < 5%, up to 30% on lip or
genitals Related to depth, location, immunosuppression
Mohs: Choosing the best for your family
Certainty of removalPatient: Convenient & FastMedical: No lesion follow-up. Cost
effective.Minimize tissue removal
Certainty allows you to take smaller margins
Important for vital structures (nose, ears, eyelids, lips, etc.)
Non-surgical treatments offered by many dermatologists can lead to bigger problems
7cm
14cm
Initial Lesion
Mohs treatedLesion (20 yrs later)
The miMOHS™ experience
Minimal pain injections We offer topical numbing cream to apply at home Patient and gentle techniques to avoid the “stick and sting”
Creating a comfortable environment Friendly staff, relaxed atmosphere Bottle water and coffee, relaxing music, private waiting area
Subtle & sophisticated: Taking less tissue without compromising certainty Minimize surgical injury Minimal cautery smoke Simpler closures when possible, speeding post-operative healing
Instructions & Medications to treat residual pain post-procedure Antibiotics to prevent infection A personal emergency contact number A follow-up call to ensure comfort Scar revision
Chemical peel, dermabraision, or laser scar treatment
Quick facts
Melanoma is #4 diagnosed cancer, ~ 74K in 2015 In-situ is #1 stage diagnosed, ~ 64K in 2015
Indolent (in elderly) vs. early aggressive tumor types
5-10 year survival ~ 99-100%Very low risk of metastasisTreated with excision only
Treating your Melanoma in situ
Excision of 5-10 mm margins Similar drawbacks as for BCC/SCC excision
Mohs with IHC Total margin control of Mohs + immunohistochemical
stains (MART-1) to track and identify positive margins at the time of excision
577 pt study, avg f/u 2.8 yrs: < 0.5% recurrence